Related Experiment Video
Updated: Aug 23, 2025
10:29
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
Published on: January 3, 2025
1.5K
Manufacturing next-generation regulatory T-cell therapies
Katherine N MacDonald1, Kevin Salim2, Megan K Levings3
1School of Biomedical Engineering, University of British Columbia, Vancouver, BC, Canada; BC Children's Hospital Research Institute, Vancouver, BC, Canada; Michael Smith Laboratories, University of British Columbia, Vancouver, BC, Canada.
Current Opinion in Biotechnology
|November 4, 2022
Summary
Next-generation regulatory T-cell (Treg) therapies are advancing cell manufacturing. Genetic engineering and in vitro generation methods enhance Treg specificity and function for treating immune-related diseases.
Area of Science:
- Immunology
- Cell Therapy
- Genetic Engineering
Background:
- Regulatory T-cell (Treg) therapy shows promise for autoimmune diseases and transplant rejection.
- Current Treg therapies face limitations in specificity, cell number requirements, and autologous product generation.
- The field is shifting towards 'next-generation' engineered Treg therapies.
Purpose of the Study:
- To review genetic modification strategies for enhancing Treg specificity and function.
- To discuss methods for in vitro Treg generation, including gene editing and stem cell differentiation.
- To explore the applications of engineered Tregs in clinical settings.
Main Methods:
- Genetic modification of Tregs via viral transduction or gene editing.
- FOXP3 gene editing or overexpression for Treg generation.
- Differentiation of Tregs from pluripotent stem cells.
Main Results:
- Genetic modification can engineer Treg specificity and function.
- In vitro generation methods offer scalable Treg production.
- Engineered Tregs hold potential for improved therapeutic outcomes.
Conclusions:
- Engineered Tregs represent a significant advancement in cell therapy manufacturing.
- Genetic modification and in vitro generation are key to next-generation Treg therapies.
- Further research into engineered Treg applications is warranted for immune-related diseases.
